F. Marmorino

Tumor mutational load, microsatellite instability, BRCAness, and actionable alterations in metastatic colorectal cancer: Results from the TRIBE2 study

Background In the TRIBE2 study, molecularly unselected and untreated mCRC patients were randomized to receive FOLFOXIRI/bevacizumab (bev) followed by the same agents after disease progres...

T. Latiano ;

E. Tamburini ;

A. Passardi ;

Sara Lonardi ;

D. Santini ;

H. Lenz ;

A. Zaniboni ;

C. Antoniotti ;

G. Aprile ;

F. Marmorino ;

R. Bordonaro ;

G. Zucchelli ;

G. Fontanini ;

F. Corti ;

M. Korn ;

V. Conca ;

R. Moretto ;

A. Falcone ;

M. Giordano ;

C. Cremolini ;

S. Lonardj ;

C. Ugolini ;

06/30/2020

O-013: Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies.

Access the abstract

Angela Buonadonna ;

Giuliana Ritorto ;

Giacomo Allegrini ;

Carlotta Antoniotti , MD, PhD;

Sara Lonardi ;

F. Marmorino ;

G. Zucchelli ;

B. Borelli ;

R. Moretto ;

A. Falcone ;

Mariaelena Casagrande ;

G. Masi ;

Sabina Murgioni ;

C. Cremolini ;

Emanuela Dell'Aquila ;

A. Zaniboni ;

Gianluca Tomasello ;

G. Aprile ;

Federica Urbano ;

Monica Ronzoni ;

Sara Manglaviti ;

07/31/2019

Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study

Background Regorafenib is a treatment option for refractory metastatic colorectal cancer (mCRC) patients. The identification of markers to predict or monitor the efficacy of regorafenib r...

F. Marmorino ;

Filippo Pietrantonio ;

A. Boccaccino ;

C. Cremolini ;

M. Antista ;

N. Zaffaroni ;

G. Zucchelli ;

A. Martinetti ;

E. Campi ;

E. Sottotetti ;

B. Borelli ;

F. Corti ;

V. Conca ;

R. Moretto ;

M. Germani ;

A. Falcone ;

M. Giordano ;

C. Antoniotti ;

G. Masi ;

07/02/2021

FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: Updated and overall survival results of the phase II randomized AtezoTRIBE study

AtezoTRIBE (NCT03721653) is a phase II randomized trial in which unresectable mCRC pts were randomized 1:2 to 1st-line FOLFOXIRI/bev [arm A] or FOLFOXIRI/bev/atezo [arm B]. Adding atezo t...

S. Tamberi ;

M. Bensi ;

I. Toma ;

M. De Grandis ;

M. Palermo ;

A. Cappetta ;

Sara Lonardi ;

A. Catteau ;

C. Antoniotti ;

L. Boni ;

F. Marmorino ;

J. Galon ;

V. Conca ;

R. Moretto ;

Filippo Pietrantonio ;

C. Cremolini ;

A. Passardi ;

M. Ambrosini ;

L. Salvatore ;

06/25/2023

Federica Marmorino, MD, University of Pisa

Videos

Effect of Gut Microbiome Composition on Atezolizumab Efficacy Among Patients With Colorectal Cancer

07/28/2023

F. Marmorino ;

At the 2023 World Congress on Gastrointestinal Cancers, Federica Marmorino, MD, discusses the effect the gut microbiome composition may have on the efficacy of checkpoint inhibitors like atezolizumab for colorectal cancer.

At the 2023 World Congress on...

07/28/2023

Oncology